We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04781725
Recruitment Status : Recruiting
First Posted : March 4, 2021
Last Update Posted : November 17, 2021
Intensity Therapeutics, Inc.
Ontario Institute for Cancer Research
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

Brief Summary:
This is a phase II, randomized, multi-center, parallel design, window of opportunity trial evaluating intratumoral INT230-6 in up to 90 patients with early stage breast cancer. In a 2:1 randomization, patients on the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: INT230-6 Other: Saline injection Phase 2

Detailed Description:

The study comprises 2 consecutive parts. The first part will be to test safety and feasibility of the dosing procedures. Results from Part I of the study will standardise the optimal dose and frequency of INT230-6 for participants in Part II.

Part I: Open-label 2:1 randomized study of up to 30 patients. Treatment arm patients will be given up to 3 doses of INT230-6 injected weekly prior to breast surgery, at a dose based on longest diameter. The control arm patients receive no treatment.

Part II: Double-blind, 2:1 randomized study of up to an additional 60 patients. The placebo arm includes a saline injection of similar dose and frequency as the treatment arm (up to 2 doses of INT230-6/saline injected weekly prior to breast surgery).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of Intratumoral INT230-6 in Early Stage Breast Cancer: The INVINCIBLE Trial
Actual Study Start Date : March 25, 2021
Estimated Primary Completion Date : March 1, 2022
Estimated Study Completion Date : March 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Vinblastine

Arm Intervention/treatment
Experimental: INT230-6 Treated Arm

Part I: Patients will receive up to 3 doses of INT230-6 injected weekly prior to breast surgery

Part II: Patients will receive up to 2 intratumoral doses of INT230-6 (over a 15-day period) prior to breast surgery

Drug: INT230-6
INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
Other Names:
  • Cisplatin
  • Vinblastine
  • 2-hydroxybenzoylaminooctanoate (SAHO)

Other: Saline injection
Standard 0.9 % NaCl Normal Saline

Placebo Comparator: Control Arm

Part I: No intervention while awaiting surgery

Part II: Placebo saline injection

Other: Saline injection
Standard 0.9 % NaCl Normal Saline

Primary Outcome Measures :
  1. The proportion of patients achieving a CCCA defined as a reduction in the proportion of cells staining positive for Ki67 as assessed by immunohistochemistry to less than a natural logarithm, or ≤2.7%, at the post-treatment specimen. [ Time Frame: presurgical window (period from diagnosis to surgery window of 3-6 weeks) ]
    Tumor's viable plus necrotic tissue, at the post-treatment specimen.

Secondary Outcome Measures :
  1. The proportion of patients that achieved a complete pathologic response on surgical pathology as measured by the residual cancer burden index [ Time Frame: presurgical window (period from diagnosis to surgery of 3-6 weeks) ]
    Assessed by the local pathologist at the time of definitive surgery in subjects with breast cancer

  2. Immunohistochemical and gene expression markers of necrosis, apoptosis and tumor proliferation pathways. [ Time Frame: presurgical window (period from diagnosis to surgery of 3-6 weeks) ]
    Comparison of pre (diagnostic biopsy) and post treatment (surgical resection) samples

  3. Markers of immunomodulation including macrophages, NK, DC, CD4 T-cells, CD8 T-cells, regulatory T-cells. [ Time Frame: presurgical window (period from diagnosis to surgery of 3-6 weeks) ]
    Comparison of pre (diagnostic biopsy) and post treatment (surgical resection) samples

  4. Adverse effects of INT230-6 injected to breast cancers in healthy patients prior to surgery. [ Time Frame: presurgical window (period from diagnosis to surgery of 3-6 weeks) ]
    overall safety of INT230-6 injected prior to surgery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Female patients with newly diagnosed histologically confirmed primary invasive breast cancer currently not undergoing any treatment while awaiting surgery.
  2. Patients with early, operable stage I to II breast cancer amendable for complete surgical resection as assessed by treating surgical oncologist.
  3. Tumors must be clinically palpable by surgeon. Part I: ≥ 1.0 cm by palpation or on imaging. Part II: ≥ 1.5 cm by palpation or on imaging.
  4. Histologic Bloom Richardson grade ≥2.

4. Invasive ductal or lobular carcinoma, invasive carcinoma Not Otherwise Specified (NOS).

5. ECOG PS 0-2 (Appendix A). 6. The participant (or legally acceptable representative if applicable) is able to provide written informed consent for the study.

Exclusion Criteria:

  1. Locally advanced or metastatic breast cancer.
  2. Prior therapy with chemotherapy or planned neoadjuvant chemotherapy.
  3. Pre-dominant histology other than invasive ductal or lobular carcinoma or invasive carcinoma NOS.
  4. Patients with an active infection.
  5. Absolute Neutrophil Count < 1.5 x 10^9/L.
  6. Patients with pre-existing renal impairment, Creatinine clearance calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of less than 50 mL/min/1.73m2.
  7. Any serious known immediate or delayed hypersensitivity reaction(s) to vinblastine or cisplatin or idiosyncrasy to drugs chemically related to the investigational drugs.
  8. Known allergic reaction to local anesthetic (Xylocaine, Marcaine).
  9. Concurrent medical condition requiring the use of immunosuppressive medications, or systemic corticosteroids at doses of greater than 10 mg Prednisone-equivalent Topical steroids and other localized corticosteroids are permitted. Use of steroids as prophylactic treatment for subjects with contrast allergies to diagnostic imaging contrast dyes will be permitted.
  10. Concurrent use of a prohibited medication or planned use of any forbidden medications during treatment with INT230-6, or within 4 weeks prior to study drug administration, which include chemotherapy, immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer: systemic or intratumoral), other biologic therapy, investigational therapy, or hormonal therapy, cisplatin containing agents, and vinblastine containing agents while on treatment in this study. Other prohibited concomitant medications that will interact with vinblastine and cisplatin include mitomycin, phenytoin, CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin, erythromycin), nephrotoxic drugs (aminoglycosides, amphotericin), or pure pyridoxine (pyridoxine contained in multivitamin is permitted). Use of other investigational drugs (drugs not marketed for any indication) within 4 weeks prior to study drug administration not permitted.
  11. Pregnancy if patient is of childbearing age) or breast feeding.
  12. Subjects with signs/symptoms suggestive of COVID-19 or known COVID-19 positive contacts in the past 14 days would be tested as per local Public Health and/or Institutional Guidelines. If patients are COVID-19 positive at the time of screening, they would be excluded from the trial.
  13. Any underlying medical condition that, in the Principal Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events, or renders the patient ineligible to be on study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04781725

Layout table for location contacts
Contact: Angel Arnaout, MD 6137985555 anarnaout@toh.on.ca

Layout table for location information
Canada, Ontario
The Ottawa Hospital Research Institute and Cancer Center Recruiting
Ottawa, Ontario, Canada, K1Y 4E9
Contact: Angel Arnaout, MD    613-798-5555 ext 79622    aarnaout@toh.on.ca   
Sponsors and Collaborators
Ottawa Hospital Research Institute
Intensity Therapeutics, Inc.
Ontario Institute for Cancer Research
Layout table for investigator information
Principal Investigator: Angel Arnaout, MD Ottawa Hospital Research Institute
Principal Investigator: Arif Awan, MD Ottawa Hospital Research Institute
Layout table for additonal information
Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT04781725    
Other Study ID Numbers: OTT 20-11 (IT-02)
First Posted: March 4, 2021    Key Record Dates
Last Update Posted: November 17, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Ottawa Hospital Research Institute:
window of opportunity
complete pathologic response (PCR)
immune activation
cell cycle arrest
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action